Accelerated Linear Growth during Erdafitinib Treatment: An FGFR-Related, but Growth Factor and Sex Steroid-Independent Mechanism?
Hormone Research in Paediatrics · 2024
DOI: 10.1159/000540485 ↗Kurz gefasst
Fachartikel in der Zeitschrift Hormone Research in Paediatrics, 2024. Verfasst von Gabriele Hartmann und 5 weiteren Autor:innen. Beteiligte Einrichtung: Division of Pediatric Pulmonology, Allergology and Endocrinology, Department of Pediatrics and Adolescent Medicine, Medical University Vienna, Vienna…. Hauptthemen laut MEDLINE: Pyrazoles, Quinoxalines, Insulin-Like Growth Factor I, Receptor, Fibroblast Growth Factor, Type 3. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 13 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
Introduction
Growth acceleration during postnatal growth only occurs during puberty as a physiological event and during catch-up growth mediated by growth-promoting therapies in growth disorders. Here we report on novel observations of skeletal symptoms during treatment with erdafitinib, a tyrosine kinase inhibitor (TKI) prescribed on the basis of a compassionate-use program.
Methods
Analysis of anthropometric, biochemical, clinical, and radiographic data of patients with CNS tumors who revealed an unanticipated growth spurt with initiation of therapy with erdafitinib was performed retrospectively.
Results
Linear growth acceleration was independent of sex steroids and IGF1 levels, which is especially remarkable in the context of heavily pretreated pediatric neuro-oncology patients with severe growth impairment before initiation of therapy. Growth acceleration was accompanied by a distinct widening of the growth plate and enhanced metaphyseal mineralization shortly after the start of TKI therapy.
Conclusions
While targeted therapies including TKIs have become an essential part of adult cancer treatment, applications in children are still limited. Off-target effects specific to the pediatric population have been observed in various organ systems; however, knowledge about the effect of TKIs on the growing skeleton is scarce. Treatment with erdafitinib inhibits FGFR3-mediated effects and thus represents a very logical hypothetical framework of growth factor and sex steroid-independent growth acceleration.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Division of Pediatric Pulmonology, Allergology and Endocrinology, Department of Pediatrics and Adolescent Medicine, Medical University Vienna, Vienna, Austria.
- Vienna Bone and Growth Center, Vienna, Austria.
- Department of Pediatrics and Adolescent Medicine, Comprehensive Center for Pediatrics and Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria, natalia.stepien@meduniwien.ac.at.
- Department of Pediatrics and Adolescent Medicine, Comprehensive Center for Pediatrics and Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria.
Zitieren
APA
Hartmann, G., Raimann, A., Stepien, N., Azizi, A. A., Hartmann, G., & Gojo, J. (2024). Accelerated Linear Growth during Erdafitinib Treatment: An FGFR-Related, but Growth Factor and Sex Steroid-Independent Mechanism?. Hormone Research in Paediatrics. https://doi.org/10.1159/000540485
Vancouver
Hartmann G, Raimann A, Stepien N, Azizi AA, Hartmann G, Gojo J. Accelerated Linear Growth during Erdafitinib Treatment: An FGFR-Related, but Growth Factor and Sex Steroid-Independent Mechanism?. Hormone Research in Paediatrics. 2024. doi:10.1159/000540485
BibTeX
@article{Hartmann2024,
author = {Hartmann, Gabriele and Raimann, Adalbert and Stepien, Natalia and Azizi, Amedeo A and Hartmann, Gabriele and Gojo, Johannes},
title = {Accelerated Linear Growth during Erdafitinib Treatment: An FGFR-Related, but Growth Factor and Sex Steroid-Independent Mechanism?},
journal = {Hormone Research in Paediatrics},
year = {2024},
doi = {10.1159/000540485}
}
EUVIMED